News archive
Showing 717 results
January 2020
-
Media Release
Public-Private Collaboration Commits to Accelerate Access to Health Services in Africa, Reaching 1.7 Million People
Healthcare companies and philanthropies to fund training of thousands of community health workers as part of larger initiative led by Last Mile Health and Living Goods to advance universal health… -
Media Release
Public-Private Collaboration Commits to Accelerate Access to Health Services in Africa, Reaching 1.7 Million People
December 2019
-
Media Release
Novartis announces FDA filing acceptance of Xolair® (omalizumab) for treatment of nasal polyps
EAST HANOVER, N.J., Dec. 11, 2019 /PRNewswire/ -- The submission is based on positive results from the Phase III POLYP 1 and POLYP 2 studies of Xolair in adults with chronic rhinosinusitis with… -
Media Release
Novartis announces FDA filing acceptance of Xolair® (omalizumab) for treatment of nasal polyps
-
Media Release
Novartis Kymriah® demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting
- Efficacy in DLBCL confirmed results seen in the pivotal trial despite treatment of a broader population, including older and more heavily pretreated patients1-3- Fewer known CAR-T cell therapy… -
Media Release
Novartis Kymriah® demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting
November 2019
-
Media Release
New Novartis medicine Adakveo® (crizanlizumab-tmca) approved by FDA to reduce frequency of pain crises in individuals living with sickle cell disease
Sickle cell pain crises are unpredictable, severe events associated with life-threatening complications(1)Adakveo reduced the annual rate of sickle cell pain crises by 45% compared to placebo (1.63… -
Media Release
New Novartis medicine Adakveo® (crizanlizumab-tmca) approved by FDA to reduce frequency of pain crises in individuals living with sickle cell disease
-
Media Release
Novartis launches PsO at Work with music icon Cyndi Lauper to bring to life the impact psoriasis can have in the workplace
- PsO at Work provides a critical resource to help the more than 8 million Americans with psoriasis balance the demands of their jobs with managing their symptoms(1)- Lauper will highlight her PsO at… -
Media Release
Novartis launches PsO at Work with music icon Cyndi Lauper to bring to life the impact psoriasis can have in the workplace
October 2019
-
Media Release
Novartis STEP Program™ now accepting submissions for proposals that address unmet patient needs in cancer biomarker testing
- STEP Program is available to US-based nonprofit patient advocacy organizations- Recipients will receive funding to support proposals that demonstrate innovation in awareness and education, self-… -
Media Release
Novartis receives FDA approval for BEOVU®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept
In two head-to-head clinical trials, patients on BEOVU (brolucizumab-dbll) achieved vision gains that were non-inferior to aflibercept at year one with longer treatment intervals in a majority of…